Claims for Patent: 8,178,662

Summary for Patent: 8,178,662

Title:	Isolated AEBP1 genomic polynucleotide fragments from chromosome 7 and their uses
Abstract:	The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s):	Ryan; James (Augusta, GA)
Assignee:	Ryogen LLC (Suffern, NY)
Application Number:	12/533,087
Patent Claims:	1. A method of identifying a nucleotide sequence variant of SEQ ID NO: 8, or its complementary sequence comprising (a) isolating genomic DNA from a subject and (b) determining the presence or absence of a variant in said genomic DNA using a nucleic acid molecule comprising at least 20 contiguous nucleotides of an intron region of SEQ ID NO:8, wherein said intron region is selected from the group consisting of the sequence of nucleotides between positions 9015-10,641, 8122-8672, 7932-8049, 7754-7859, 7554-7628, 6662-7475, 6452-6583, 6273-6375, 5456-6218, 5353-5434, 4834-5211, 4647-4749, 4407-4502, 4053-4319, 3707-3929, 3418-3508, 3001-3237, 2570-2650, 2305-2425 and 1967-2208 of SEQ ID NO:8, or its complementary sequence. 2. A method for detecting the presence or absence of a non-coding nucleic acid sequence specific to the nucleic acid molecule of SEQ ID NO:8 in a sample, said method comprising contacting a sample with a nucleic acid molecule comprising at least 20 contiguous nucleotides of an intron region of SEQ ID NO:8, wherein said intron region is selected from the group consisting of the sequence of nucleotides between positions 9015-10,641, 8122-8672, 7932-8049, 7754-7859, 7554-7628, 6662-7475, 6452-6583, 6273-6375, 5456-6218, 5353-5434, 4834-5211, 4647-4749, 4407-4502, 4053-4319, 3707-3929, 3418-3508, 3001-3237, 2570-2650, 2305-2425 and 1967-2208 of SEQ ID NO:8, or its complementary sequence. 3. A method of identifying a nucleotide sequence variant of SEQ ID NO:8, or its complementary sequence comprising (a) isolating genomic DNA from a subject, and (b) determining the presence or absence of a nucleotide sequence variation in said genomic DNA by comparing the nucleotide acid sequence of SEQ ID NO:8, or its complementary sequence, with the nucleotide sequence of the isolated genomic DNA of (a) and establishing if and where a difference occurs between the two nucleic acid sequences thereby identifying a nucleotide sequence variant of SEQ ID NO:8, or its complementary sequence. 4. The method of claim 3, wherein the presence or absence of a nucleotide sequence variation is determined in a 5'-noncoding region, wherein said 5'-noncoding region is between positions 1-1300 of SEQ ID NO:8, or its complementary sequence, 3'-noncoding region, wherein said 3'-noncoding region is between positions 10894-16161, or its complementary sequence, or intron region of SEQ ID NO: 8, wherein said intron region is selected from the group consisting of the sequence of nucleotides between positions 9015-10,641, 8122-8672, 7932-8049, 7754-7859, 7554-7628, 6662-7475, 6452-6583, 6273-6375, 5456-6218, 5353-5434, 4834-5211, 4647-4749, 4407-4502, 4053-4319, 3707-3929, 3418-3508, 3001-3237, 2570-2650, 2305-2425 and 1967-2208 of SEQ ID NO:8, or its complementary sequence. 5. A method of detecting the presence or absence of a polynucleotide having the nucleic acid sequence depicted in SEQ ID NO:8, said method comprising (a) contacting the sample with a nucleic acid molecule comprising at least 20 contiguous nucleotides of an intron region of SEQ ID NO:8, wherein said intron region is selected from the group consisting of the sequence of nucleotides between positions 9015-10,641, 8122-8672, 7932-8049, 7754-7859, 7554-7628, 6662-7475, 6452-6583, 6273-6375, 5456-6218, 5353-5434, 4834-5211, 4647-4749, 4407-4502, 4053-4319, 3707-3929, 3418-3508, 3001-3237, 2570-2650, 2305-2425 and 1967-2208 of SEQ ID NO:8, or its complementary sequence under stringent hybridization conditions and (b) determining whether the nucleic acid molecule in (a) binds to a polynucleotide in the sample, wherein binding of a polynucleotide of the sample to the nucleic acid molecule of (a) detects the presence of a polynucleotide having the nucleic acid sequence depicted in SEQ ID NO:8, or its complementary sequence. 6. An isolated nucleic acid molecule consisting of a sequence of at least 20 contiguous nucleotides within an intron region of SEQ ID NO:8, or its complementary sequence, wherein said intron region is selected from the group consisting of the sequence of nucleotides between positions 9015-10,641, 8122-8672, 7932-8049, 7754-7859, 7554-7628, 6662-7475, 6452-6583, 6273-6375, 5456-6218, 5353-5434, 4834-5211, 4647-4749, 4407-4502, 4053-4319, 3707-3929, 3418-3508, 3001-3237, 2570-2650, 2305-2425 and 1967-2208 of SEQ ID NO:8, or its complementary sequence. 7. The isolated nucleic acid molecule of claim 6, wherein said nucleic acid molecule is a synthetic polynucleotide. 8. The isolated nucleic acid molecule of claim 6, wherein said nucleic acid molecule is DNA or RNA. 9. A kit comprising one or more nucleic acid molecules of claim 6.

Details for Patent 8,178,662

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-09-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-09-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-09-21